[HTML][HTML] Daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with previously treated multiple myeloma: three-year …
Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow …
MV Mateos, P Sonneveld, V Hungria… - Clinical Lymphoma …, 2020 - ohsu.pure.elsevier.com
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow …
MV Mateos, P Sonneveld, V Hungria… - Clinical Lymphoma …, 2019 - repub.eur.nl
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow …
M Mateos, P Sonneveld, V Hungria, AK Nooka… - CLINICAL LYMPHOMA …, 2020 - air.unimi.it
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
[HTML][HTML] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year …
MV Mateos, P Sonneveld… - Clinical …, 2020 - clinical-lymphoma-myeloma …
Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow …
MV Mateos, P Sonneveld, V Hungria… - Clinical Lymphoma …, 2020 - ohsu.elsevierpure.com
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow …
MV Mateos, P Sonneveld, V Hungria… - … Myeloma & Leukemia, 2019 - europepmc.org
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in
Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR …
Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR …
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow …
MV Mateos, P Sonneveld, V Hungria… - Clinical lymphoma …, 2020 - pubmed.ncbi.nlm.nih.gov
Background In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
[PDF][PDF] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year …
MV Mateos, P Sonneveld, V Hungria… - … Lymphoma, Myeloma & …, 2020 - core.ac.uk
CASTOR showed the significant clinical benefit of daratumumab plus bortezomib and
dexamethasone for patients with previously treated multiple myeloma. With w3 years …
dexamethasone for patients with previously treated multiple myeloma. With w3 years …
[引用][C] Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year …
MV Mateos, P Sonneveld… - Clinical …, 2020 - produccioncientifica.usal.es
Background: In the phase III CASTOR study in relapsed or refractory multiple myeloma,
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …
daratumumab, bortezomib, and dexamethasone (D-Vd) demonstrated significant clinical …